Nature press release on DiGeorge syndrome paperFebruary 23, 2001[410097] LIFELINES: CATCH 22 (pp97–101) In the 1 March issue of Nature, researchers from Baylor College of Medicine in Texas pinpoint the gene behind one of the most common genetic diseases to affect humans: DiGeorge syndrome. The disease results in a broad spectrum of symptoms, including heart abnormalities, disruption of the immune system and facial morphology. DiGeorge syndrome affects around 1 in 4,000 babies born, and next to Down syndrome it is the most common genetic cause of heart defects. DiGeorge syndrome is caused by deletions of large sections of DNA from our smallest chromosome: chromosome 22. Up to one tenth of this chromosome’s 33 million DNA base pairs can be missing from the genome of DiGeorge syndrome patients. A large number of genes lie within this section of DNA (known as 22q11.2), but until now researchers have been unable to pinpoint the exact gene, or genes, which directly cause the disease. Antonio Baldini and colleagues used state-of-the-art genetic techniques to test a number of candidate genes in a mouse model of DiGeorge syndrome. This model allows them to identify a gene known as Tbx1— a control gene that switches on the expression of other genes during development—as being responsible for the main cardiac symptoms of the disease. The finding brings to an end the long search for a gene involved in DiGeorge syndrome, and provides scientists with insight into both the disease, and the normal development of complex organs like the heart. CONTACT: Antonio Baldini tel +1 713 798 6519, e-mail baldini@bcm.tmc.edu Nature Publishing Group Reference |
|||||||||||||||||||||
| Related DNA Current Events and DNA News Articles Deciphering the regulatory code Embryonic development is like a well-organised building project, with the embryo's DNA serving as the blueprint from which all construction details are derived. Male sabertoothed cats were pussycats compared to macho lions Despite their fearsome fangs, male sabertoothed cats may have been less aggressive than many of their feline cousins, says a new study of male-female size differences in extinct big cats. Autism Consortium symposium draws record number of researchers, advocates, parents for autism update The Autism Consortium, an innovative collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), held its fourth annual symposium on October 28th, 2009, at Harvard Medical School in Boston. Researchers identify drug candidate for treating spinal muscular atrophy A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. Conserving historic apple trees The apple trees of yesteryear are slowly disappearing. Many apple varieties common in the United States a century ago can no longer be found in today's orchards and nurseries. Tiny injector to speed development of new, safer, cheaper drugs It's no bigger than a stamp packet but it has the potential to allow rapid development of a new generation of drugs and genetic engineering organisms, and to better control in-vitro fertilization. Taking aim at mysterious DNA structures in the battle against cancer Designers of anti-cancer drugs are aiming their arrows at mysterious chunks of the genetic material DNA that may play a key role in preventing the growth and spread of cancer cells, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers The white shark may be the ultimate loner of the ocean, cruising thousands of miles in a solitary trek, but a team of researchers has discovered that the sharks have maintained such a consistent pattern of migration that over tens of thousands of years the white sharks in the northeastern Pacific Ocean have separated themselves into a population genetically distinct from sharks elsewhere in the world. Clinical tests begin on medication to correct Fragile X defect NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. A Potential Anti-cancer Agent Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. More DNA Current Events and DNA News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||